Abstract 277P
Background
To characterize ductal adenocarcinoma of the prostate by comparing VASH1 expression levels in ductal and acinar adenocarcinoma of the prostate.
Methods
125 patients who underwent radical prostatectomy or transrectal resection over the past 5 years, 14 patients diagnosed with ductal adenocarcinoma and 20 patients with acinar adenocarcinoma with Gleason scores of 4+4 were included in the study. VASH1 density was taken as the number of activated endothelial cells (number of vessels per mm2), microvessel density (MVD) was determined through CD34 expression, all results were obtained by immunohistochemistry. The main method for evaluating the results was to determine the presence of a relationship between MVD and VASH1 density in ductal and acinar adenocarcinoma, the secondary method for evaluating the results was the oncological outcomes of these forms of cancer.
Results
9 patients (64.3%) with ductal adenocarcinoma were diagnosed with advanced clinical stage and 5 patients (35.7%) died of cancer during a median follow-up period of 56.0 months. VASH1 density (mean ± SD) in ductal and acinar adenocarcinoma was 45.1 ± 18.5 vs. 16.1 ± 21.0 (p < 0.001), respectively, while MVD (mean ± SD) in ductal and acinar adenocarcinoma was 65.3 ± 21.9 versus 80.8 ± 60.7. (p = 0.666), respectively. The five-year survival rate for high and low VASH1 expression was 70.0% and 100.0% (p = 0.006), respectively. High expression of VASH1 and diagnosis of ductal adenocarcinoma were important predictors of survival.
Conclusions
Ductal adenocarcinoma has more aggressive growth and higher expression of VASH1 than acinar adenocarcinoma, with MVD rates being equivalent in both forms of prostate cancer. The obtained results suggest that the level of VASH1 expression may be a new biomarker for the aggressive course of ductal adenocarcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Republican Cancer Research Center of Uzbekistan.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer
Presenter: Mukul Singh
Session: Poster Display
Resources:
Abstract
453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial
Presenter: Qiaoqi Li
Session: Poster Display
Resources:
Abstract
454P - A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Presenter: Akira Ooki
Session: Poster Display
Resources:
Abstract
455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Presenter: Matti Aapro
Session: Poster Display
Resources:
Abstract
456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism
Presenter: Sang Bo Oh
Session: Poster Display
Resources:
Abstract
458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study
Presenter: Sujeong Shin
Session: Poster Display
Resources:
Abstract
460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients
Presenter: Dyta William
Session: Poster Display
Resources:
Abstract
461P - A randomized controlled trial of yoga in locally advanced non-small cell lung cancer patients receiving chemoradiotherapy
Presenter: Indranil Khan
Session: Poster Display
Resources:
Abstract